shadow_tr

The People of Tulane Cancer Center Research


Matthew BurowMatthew E. Burow, Ph.D.
Assistant Professor of Medicine
Section of Hematology and Medical Oncology
Adjunct Assistant Professor of Surgery
Tulane Cancer Center Program Member

Contact Information
Email: mburow@tulane.edu
Phone: 504-988-6688
Address: 1430 Tulane Ave., Box SL-78, New Orleans, LA 70112

Biographical Narrative

Dr. Burow received his B.S. in Biology in 1994 at the University of Southern Mississippi. He completed his Ph.D. in 1998 at Tulane University from the Interdisciplinary Graduate Program in Molecular and Cellular Biology. Dr. Burow carried out his post-doctoral studies with Dr. John McLachlan at the Tulane/Xavier Center for Bioenvironmental Research. He was appointed in 2000 as a Research Assistant Professor in the Department of Pharmacology. In 2002 Dr. Burow accepted his current position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine with an appointment as an Adjunct Assistant Professor in the Department of Surgery. Dr. Burow's primary research interests focus on understanding the molecular mechanisms that control estrogen receptor mediated gene expression and anti-estrogen resistance in breast carcinoma cells and the way that cell survival and apoptotic signaling pathways regulate the progression of breast carcinoma to a hormone independent and drug resistant phenotype.

Selected Publications
Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS. Cross-talk between phosphatidylinositol-3 kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 275(13): 9628-9635 (2000

)

Burow ME, Weldon CB, Melnik LI, BN Duong, Collins-Burow BM, Klippel A, Beckman BS, McLachlan JA. Phosphatidylinositol 3-kinase/AKT mediated regulation of NF-_B signaling events as a mechanism for suppression of TNF-induced apoptosis. Biochem and Biophys Res Comm 271: 342-345 (2000)

Burow ME, Boue BS, Collins-Burow BM, Melnik LI, Duong BN, Li SF, Wiese T, Cleavland E, McLachlan JA. Phytochemical glyceollins, isolated from soy, mediate anti-hormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab 86(4): 1750-1758 (2001)

Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS. Oestrogen-mediated suppression of TNF-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. J Steroid Biochem Mol Bio 78(5): 409-418 (2001)

Frigo DE, Duong BN, Melnik LI, Schief L, Collins-Burow BM, Pace DK, McLachlan JA, Burow ME. Flavonoid phytochemicals regulate activator Protein-1 signal transduction pathways in endometrial and kidney stable cell lines. J Nutr 132(7): 1848-1853 (2002)

Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott SE, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132(2):293-301 (2002)

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow ME, Gordon A, Dhurandhar NM, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine 9(5): 562-567 (2003)

Simstein R, Burow ME, Parker A, Weldon CB, Beckman BS. "Apoptosis, Chemoresistance and Breast Cancer: Insights from the MCF-7 Cell Model System". Exp Biol Med 228(9):995-1003 (2003)

Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA. Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis 25(2): 249-261 (2004)

Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond TG, Tang Y, Beckman BS. Novel Ceramide Analogues as Potential Chemotherapeutic Agents in Breast Cancer. J Pharmacol Exp Therapeut 309(2): 523-532 (2004)

Weldon CB, Parker AP Patten D, Elliot S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24(6): 1473-1480 (2004)

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng PC, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Daniel B, Gordon A, Myers L, Disis ML, Knuston K, Lackner A, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10(9):942-949 (2004)

 

1430 Tulane Ave, New Orleans, LA 70112 504-988-5263 medsch@tulane.edu